|
|
| |
| Education |
- University of Georgia, Bachelor of Science in Pharmacy, 1986
- Medical College of Virginia/Virginia Commonwealth University, Doctor of Pharmacy, 1988
|
| Research Interests |
| The overall goal of my research program is the clinical development of target peptide toxins for the treatment of cancer. My major focus is investigating the development of an immune response to peptide toxins and its clinical impact. Currently, we are developing a truncated diphtheria toxin (DT) linked to human GM-CSF for the treatment of acute myeloid leukemia. Future studies include DT linked to interleukin-3 for the treatment of myeloid malignancies and the investigation of Anthrax and Pseudomonas toxins. |
| Selected Publications |
- Hall PD, Razzouk BI, Willoughby TE, McLean TW, Frankel AE. The majority of children and adolescents with acute myeloid leukemia have detectable anti- DT388GMCSF IgG concentrations but at concentrations that do not preclude in vivo activity. J Ped Hematol Oncol 2002;24:521-6.
- Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/GM-CSF protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002;8:1004-13.
- Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 2001; 100(2):191-7.
- Hotchkiss CE, Hall PD, Cline JM, Willingham MC, Kreitman RJ, Gardin J, Latimer A, Ramage J, Feely T, Frankel AE. Toxicology and Pharmacokinetics of DTGM, a fusion toxin consisting of a truncated cynomolgus monkeys. Toxicol Appl Pharmacol 1999;158:152-60.
- Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia 1999;13(4):629-33.
|
|
|
